Drugs and Cosmetics rules, 2013 India
|
|
- Bertha Henry
- 5 years ago
- Views:
Transcription
1 Drugs and Cosmetics rules, 2013 India Dr.Pankaj Shah Professor, Dept of Community Medicine, SRMC & RI, & Member Secretary, IEC II, SRU, Chennai
2 Three important amendments 30 th Jan St Feb th Feb 2013 Please Verify all details from the amendments from. The ppts are only an attempt to simply.
3 Important issues Compensation for clinical trial related injury and death Reporting system Informed consent IEC functioning Inspection by Authorities etc.
4 Compensation for clinical trial related injury and death Free Medical management as long as required for the injury to clinical trial subjects In addition, financial compensation to be provided for injury and death to nominee (s) including in-utero injury To be borne by sponsor, its representative or investigator as sponsors whoever obtained permission from the Licensing authority
5 When to provide financial compensation Adverse effect of investigational product (s). Any clinical trial procedures involved in the study. Violations from approved protocols Failure of inv. Pro. To provide intended therapeutic effect Use of placebo in placebo controlled trials
6 When to provide financial compensation Adverse effects due to concomitant medication excluding standard care necessitated part of approved protocol. Injury to child in-utero
7 Adverse events Serious: untoward medical occurrence associated with death, hospitalization (OP study), Prolongation of hospitalization (IP study), persistence or significant disability or incapacity, congenital anomaly or birth defect or life threatening Non-serious:
8 Serious and unexpected adverse events Investigator will report all serious and unexpected adverse events to Licensing authority, sponsor or his representative and IEC within 24 hrs of the occurrence of event as per appendix XI
9 Serious adverse events Other than death: a) Sponsor: 1. Report after due analysis to Chairman IEC, Licensing authority and head of the institution of the trial site within ten calendar days of the event. Death a) Sponsor: 1. Report to Head of institution of the trial site(at the earliest). 2. Report after due analysis to Chairman IEC, Chairman, Expert Committee with copy of report to Licensing authority and head of institution within ten calendar days of the event.
10 Serious adverse events Other than death: b) Chairman IEC: 1. Report after due analysis along with opinion on financial compensation if any to Licensing authority within 21 calendar days of the event. Death b) Chairman IEC: 1. Report after due analysis along with opinion on financial compensation to Expert Committee with copy of report to Licensing authority within 21 calendar days of the event.
11 Serious adverse events Other than death: c) Independent expert committee: 1. It may be formed if required for finding out cause of the event and quantum of compensation. 2. No direct reporting of IEC to Independent expert committee Death c) Expert Committee: 1. finding out cause of the event and quantum of compensation. 2. Report to Licensing authority within 30 calendar days of the receiving report of IEC. (IEC should send report earlier for participants welfare)
12 Serious adverse events Other than death: c) Licensing authority: 1. finding out cause of the event and quantum of compensation (may be from Independent expert committee). 2. Pass the order within three months of receiving report of the event. Death c) Licensing authority: 1. finding out cause of the event and quantum of compensation from Independent expert committee). 2. Pass the order within three months of receiving report of the event.
13 Serious adverse events For all serious adverse events- sponsor its representative or investigator as sponsor has to act on the orders within 30 days of the receipt of the order.
14 Reporting system In addition to earlier reporting system: Sponsor undertaking to provide compensation while applying to Licensing authority for clinical trial permission. Failure to comply with compensation guidelines: Warning letters, trial rejection, trial discontinuation and debar all inovlved for future trials. Reporting the SAEs to other sites (? Holds true)
15 Periodic Safety Update Reports (PSURs) All relevant clinical and non-clinical safety data should cover only the period of the report (interval data). The PSURs shall be submitted every six months for the first two years after approval of the drug is granted to the applicant. For subsequent two years the PSURs need to be submitted annually. Licensing authority may extend the total duration of submission of PSURs if it is considered necessary in the interest of public health. PSURs due for a period must be submitted within 30 calendar days of the last day of the reporting period. However, all cases involving serious unexpected adverse reactions must be reported to the licensing authority within 15 days of initial receipt of the information by the applicant. (reporting changes)
16 Informed consent NFORMED CONSENT 1. Checklist for study Subject s informed consent documents 1.1 Essential Elements: 1.Statement that the study involves research and explanation of the purpose of the research 2.Expected duration of the Subject's participation 3.Description of the procedures to be followed, including all invasive procedures and 4.Description of any reasonably foreseeable risks or discomforts to the Subject 5. Description of any benefits to the Subject or others reasonably expected from research. If no benefit is expected Subject should be made aware of this. 6. Disclosure of specific appropriate alternative procedures or therapies available to the Subject. 7.Statement describing the extent to which confidentiality of records identifying the Subject will be maintained and who will have access to Subject s medical records 8. Trial treatment schedule(s) and the probability for random assignment to each treatment (for randomized trials) 9. Compensation and/or treatment(s) available to the Subject in the event of a trial-related injury (to be modified) 10An explanation about whom to contact for trial related queries, rights of Subjects and in the event of any injury 11The anticipated prorated payment, if any, to the Subject for participating in the trial 12 Subject's responsibilities on participation in the trial 13 Statement that participation is voluntary, that the subject can withdraw from the study at any time and that refusal to participate will not involve any penalty or loss of benefits to which the Subject is otherwise entitled 14 Any other pertinent information
17 Modification of point 9 of Serial Statement describing the financial compensation and medical management as under: a) In the event of an injury occurring to the clinical trial subject, such subject shall be provided free medical management as long as required. b) In the event of a trial related injury and death, the sponsor or his representative, whosoever has obtained permission from the Licensing Authority for the conduct of the clinical trial, shall provide financial compensation for the injury or death.
18 Serial number 2 2. Format of informed consent form for Subjects participating in a clinical trial Informed Consent form to participate in a clinical trial Study Title: Study Number: Subject s Initials: Subject s Name: Date of Birth / Age: (lot of additions here) i)i confirm that I have read and understood the information sheet dated for the above study and have had the opportunity to ask questions. [ ] iii) To iv) points
19 Additions Address of the subject: ] Qualification: Occupation: Student/selfemployed/Service/House wife/ others (please tick as appropriate) Annual income of the subject: Name of the address of the nominee (s) and his relation to the subject (for the purpose of the compensation in case of the trial related deaths)
20 Signature (or Thumb impression) of the Subject/Legally Acceptable Representative: Date: / / Signatory s Name: Signature of the Investigator: Date: / / Study Investigator s Name: Signature of the Witness Date: / / Name of the Witness: Additions here: (copy of the patient information sheet and duly filled informed consent form shall be handed over tot the subject or his/her attendant).
21 IEC and its functioning Start approving clinical trial only after IEC registration Deadline for existing committee is over. Registration for 3 years from the date of issue. a) If application for renewal given three month before expiry, registration continues to be inforce until the orders are passed by the authority. b) change in membership or constitution are informed to licensing authority in writing.
22 IEC and its functioning Review and accord approval of clinical trial Ongoing review of the trial at regular intervals Opinion for Serious adverse events. Allow inspectors for inspection Scope, composition, Quorum requirement maintenance of records etc. Conflict of interest of members in writing and recorded in minutes of the meeting.
23 IEC and its functioning Importance of SOPs In general For vulnerable population Importance of training for new and exising committee members. Policy to monitor Policy for conflict of interest Minutes to be signed by Chairman.
24 Inspections
25 Thank you
Drugs and Cosmetics (First Amendment) Rules, 2013
Ministry : Ministry of Health and Family Welfare Department/Board : Health Notification No. : GSR53(E) Date of Notification : 30.01.2013 Drugs and Cosmetics (First Amendment) Rules, 2013 G.S.R.53(E).--Whereas
More informationFERCI MODEL SOPs. [The IEC members (author/s, reviewer/s) and Chairperson will sign and date the SOP on this first page]
Title: SOP Code: SOP 12/V1 [The IEC members (author/s, reviewer/s) and Chairperson will sign and date the SOP on this first page] Prepared by: Dr. Padmaja Marathe, FERCI Member (Signature with Date) Reviewed
More informationThe SOP applies to all human subject research falling under the purview of the University of Missouri Institutional Review Board.
Institutional Review Board.... University of Missouri-Columbia.. Standard Operating Procedure Informed Consent Types and Elements Informed Consent Types and Elements Effective Date: December 12, 2005 Original
More informationSponsor Responsibilities. Roles and Responsibilities. EU Directives. UK Law
EU Directives Pharmacovigilance Legislation, SOPs and Reporting Louise Boldy, Governance & Safety Manager David Martin, Pharmacovigilance Monitor EU Legislation 2001/20/EC 2005/28/EC EudraLex Vol 10 UK
More informationTITLE: Reporting Adverse Events SOP #: RCO-204 Page: 1 of 5 Effective Date: 01/31/18
SOP #: RCO-204 Page: 1 of 5 1. POLICY STATEMENT: The research team is responsible for recognizing changes in subject health that may qualify as adverse events, classifying those results as defined in the
More informationBIMO SITE AUDIT CHECKLIST
Item AUTHORITY AND ADMINISTRATION FOR STUDIES INVOLVING HUMAN DRUGS, BIOLOGICS AND DEVICES 1. Compare the Investigator Agreement with the information provided by the assigning Center. Auditor will check
More informationStudy Management SM STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting
Study Management SM 306.00 STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick M. Schnell, MD,
More informationI2S2 TRAINING Good Clinical Practice tips. Deirdre Thom Neonatal Nurse Coordinator
I2S2 TRAINING Good Clinical Practice tips Deirdre Thom Neonatal Nurse Coordinator Content Principal investigator (slides 3-5) Delegation and delegation log (slides 6-7) Informed consent (slides 8-15) Data
More informationRoles & Responsibilities of Investigator & IRB
Roles & Responsibilities of Investigator & IRB Jaranit Kaewkungwal Mahidol University Regulatory & Guidelines Regulatory & Guidelines GCP & Computer / Database Management Systems International Conference
More informationSAINT AGNES MEDICAL CENTER CLINICAL RESEARCH CENTER Fresno, California. STANDARD OPERATING PROCEDURES Institutional Review Board
SAINT AGNES MEDICAL CENTER CLINICAL RESEARCH CENTER Fresno, California STANDARD OPERATING PROCEDURES Institutional Review Board Date Effective: April 26, 2001 Index No. R 1217 Date Last Revised: 0 Date
More informationDr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015
18 August 2015 Role & Responsibilities of Principal Dr. R. Sathianathan Professor of Psychiatry, SRMC, Porur & Former Director, Institute of Mental Health, Chennai Principal Investigators & GOOD CLINICAL
More informationETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM
ETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM Outline Introduction Composition Responsibilities of IEC Responsibilities
More informationETHICAL AND REGULATORY CONSIDERATIONS
CONSIDERATIONS Office for Office for Human Research Protections The Office for Office for Human Research Protections (OHRP) is an administrative subdivision within the U.S. Department of Health and Human
More informationStandard Operating Procedure
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-07-004 Recording, managing and reporting Adverse Events for Clinical Trials of Investigational Medicinal Products and trials of Advanced
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Safety Reporting in CTIMPs and ATMPs SOP number: TM 003 SOP category: Trial Management Version number: 03 Version date:
More informationStudy Guide for Emergency Care Clinicians. (Version /09/2014)
Study Guide for Emergency Care Clinicians (Version 1.2 26/09/2014) Notes 1. These learning materials are aimed primarily at paramedics, ambulance nurses, emergency care practitioners and doctors recruiting
More informationRoles of Investigators in the Managements of Clinical Trials
Roles of Investigators in the Managements of Clinical Trials Chii-Min Hwu, M.D. Section of General Medicine Department of Medicine Taipei Veterans General Hospital Learning Objectives PI Outlines How to
More informationUNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD REPORTING UNANTICIPATED PROBLEMS INCLUDING ADVERSE EVENTS
UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD REPORTING UNANTICIPATED PROBLEMS INCLUDING ADVERSE EVENTS I. PURPOSE To specify the procedures for reporting unanticipated problems,
More informationSTUDY INFORMATION POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812)
POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812) Purpose: Investigators who initiate and submit an IDE application to the FDA assume the responsibilities of both
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Safety Reporting in CTIMPs and ATMPs SOP number: TM-003 SOP category: Trial Management Version number: 04 Version date:
More informationSafety Reporting in Clinical Research Policy Final Version 4.0
Safety Reporting in Clinical Research Policy Final Version 4.0 Category: Summary: Equality Assessment undertaken: Impact Policy The Medicines for Human Use (Clinical Trials) Regulations 2004 and subsequent
More informationI. Scope This policy defines unanticipated problems and adverse events and establishes the reporting process and timeline.
Human Research Protection Program Policies & Procedures Unanticipated Problems and Adverse Events Version 3.0 Date Effective: 11.9.2012 Research Integrity Office Mail code L106-RI Portland, Oregon 97239-3098
More information(Type inside gray boxes, cells will expand) A. EIGHT POINT CRITERIA for IRB Review
Page 1 of 5 IRB Reviewers 8-Point Analysis Form Based on Federal Policy for the Protection of Human Subjects, Criteria for IRB Approval of Research (45 CFR 46.111) Protocol ID #/Title: Date of Review:
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL REPORTING ADVERSE DRUG REACTIONS IN SOUTH AFRICA IMPORTANT NOTE This guideline applies only to the reporting of SAEs during clinical trials. An update of the guideline for this
More informationGeneral Procedure - Institutional Review Board
General Procedure - Institutional Review Board Purpose: The primary purpose of the Institutional Review Board (IRB) is to protect the welfare of human subjects used in research. All research requests meeting
More informationInstitutional Review Board (previously referred to as Human Participants Research Board) Updated January 2004
Institutional Review Board (previously referred to as Human Participants Research Board) Updated January 2004 All research requests meeting the following conditions must be reviewed by the Institutional
More informationTHE BOARD OF THE EURASIAN ECONOMIC COMMISSION RESOLUTION. dated December 22, 2015 N 174
THE BOARD OF THE EURASIAN ECONOMIC COMMISSION RESOLUTION Dated December 22, 2015, N 174 ON APPROVAL OF REGULATIONS OF MEDICAL DEVICE SAFETY, QUALITY AND EFFECTIVENESS MONITORING In accordance with paragraph
More informationAPEC Preliminary Workshop: Review of Drug Development in Clinical Trials
APEC Preliminary Workshop: Review of Drug Development in Clinical Trials Session 9 B Clinical Trial Assessment Patient Protection Informed Consent Susan D Amico Vice President and Global Head Clinical
More informationKeele Clinical Trials Unit
Keele Clinical Trials Unit Standard Operating Procedure (SOP) Summary Box Title Safety Reporting and Pharmacovigilance SOP Index Number SOP 20 Version 4.0 Approval Date 31-Jan-2017 Effective Date 14-Feb-2017
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Adverse Event Identification, Recording and Reporting in Clinical Trials of Investigational Medicinal SOP-RES-019 Version Number 2 Issue Date 08 th Dec
More informationMarie-Claire Rickard, RG and GCP Manager Jimena Lovos, Quality Assurance Manager Elizabeth Clough, R&D Governance Operations Manager
Standard Operating Procedures (SOP) for: Pharmacovigilance processing for the JRMO SOP Number: 26c Version Number: V1 Effective Date: 5/8/16 Review Date: 5/8/17 Author: Reviewer: Reviewer: Authorisation:
More informationUniversity of South Carolina. Unanticipated Problems and Adverse Events Guidelines
University of South Carolina Unanticipated Problems and Adverse Events Guidelines These guidelines define the procedures of USC for addressing unanticipated problems involving risks to research participants
More informationBiomedical IRB MS #
Department for Human Research Protections Institutional Review Boards Biomedical IRB MS # 1035 419-383-6796 IRB.Biomed@utoledo.edu Social, Behavioral and Educational IRB MS # 944 419-530-6167 IRB.SBE@utoledo.edu
More informationResearch Adverse Event and Safety Reporting Procedures Outcome Statement: Title:
Title: Research Adverse Event and Safety Reporting Procedures Outcome Statement: Research Teams will be able to correctly identify and report Adverse Events and complete Annual Safety Reports for research
More informationPROMPTLY REPORTABLE EVENTS
PROMPTLY REPORTABLE EVENTS PURPOSE AND SCOPE To define the structure and responsibility for reporting unanticipated problems that occurs during the conduct of research. APPLICABLE REGULATIONS Policy II.02
More informationM. Rickard, Research Governance and GCP Manager R. Fay Research Governance and GCP Manager Elizabeth Clough, Governance Operations Manager
Standard Operating Procedures (SOP) for: Pharmacovigilance and Safety Reporting for Sponsored non-ctimps SOP Number: 26b Version 2.0 Number: Effective Date: 29th November 2015 Review Date: 3 rd December
More informationAnnex VIIIA Guideline for correct preparation of a model patient information sheet and informed consent form (PIS/ICF)
DEPARTMENT OF MEDICINAL PRODUCTS FOR HUMAN USE Annex VIIIA Guideline for correct preparation of a model patient information sheet and informed consent form (PIS/ICF) Version 10 th November 2016 Date of
More informationSTANDARD OPERATING PROCEDURE SOP 205
STANDARD OPERATING PROCEDURE SOP 205 Adverse Events: Identifying, Recording and Reporting for CTIMPs Sponsored by the Norfolk and Norwich University Hospital NHS Foundation Trust Version 2.3 Version date
More informationGuidelines for Review of Research Involving Human Subjects
Institutional Review Board Assumption College Guidelines for Review of Research Involving Human Subjects Table of Contents: Page General Guidelines........ 1 Scope and Purpose of IRB Review...... 1 Basis
More informationGCP INSPECTION CHECKLIST
(This list is not all inclusive; item may be added &/or deleted as per the Study/Site/Sponsor/Lab) I. General. Name and address of the clinical trial site Tel. No. & e- mail:. Date of Inspection. Inspection
More informationUNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM
Gilead Sciences, Inc. GS-US-248-0123, Amendment 1, 19-JUN-2012 A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with
More informationIRB Federal Regulations Comparison Table 4/24/01 as updated through 10/31/01
Legal Authority 45 CFR Part 46 21 USC 321-392; 21 CFR, Parts 50 and 56 Coverage All research involving human subjects conducted, All clinical investigations regulated by the FDA, including supported or
More informationDANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR HUMAN SUBJECT RESEARCH
SOP #: CON-100 Page: 1 of 9 Effective Date: 2/28/17 1. POLICY STATEMENT: The research team is responsible for obtaining and documenting the informed consent of each subject who participates in research.
More informationIDENTIFYING, RECORDING AND REPORTING ADVERSE EVENTS FOR CLINICAL INVESTIGATIONS OF MEDICAL DEVICES
IDENTIFYING, RECORDING AND REPORTING ADVERSE EVENTS FOR CLINICAL INVESTIGATIONS OF MEDICAL DEVICES DOCUMENT NO.: CR012 v2.0 AUTHOR: Raymond French ISSUE DATE: 18 September 2017 EFFECTIVE DATE: 02 October
More informationAdverse Event Reporting
Adverse Event Reporting The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.thh.nhs.uk/departments/research/research.htm
More informationIssues of. Informed Consent. Mitchell E. Parrish, JD, RAC, CIP Regulatory Attorney
Issues of Informed Consent Mitchell E. Parrish, JD, RAC, CIP Regulatory Attorney Part I Part II Regulatory Requirements Key Considerations Part III Elements of Consent Part IV Summary 2 PART I 3 Informed
More informationDetails: Approval: Distribution & Storage: Pharmacovigilance for Researchers for UoL / LTHT Sponsored CTIMPs. Standard Operating Procedure
Details: Author: Razwan Mahroof - QA Clinical Trials Monitor SOP Pages: 10 Version No. of replaced SOP: 1.0 Effective date of replaced SOP: 04 December 2015 Approval: Version No: of the SOP being approved.
More informationSOP: New Revised Reviewed Effective Date: 08 October Approved by : Supervisor/Manager Risk/Ethics Sr. Mgmt Committees Board/Councils
Title: Assessment of Study Feasibility Manual: RI MUHC Policies and Procedures Human Research SOPs Originating Dept/ Service: RI MUHC Division of Clinical Research SOP: New Revised Reviewed Effective Date:
More informationPART A. In order to achieve its objectives, this Code embodies a number of functional requirements. These include, but are not limited to:
PART A MANDATORY REQUIREMENTS REGARDING THE PROVISIONS OF CHAPTER XI-2 OF THE INTERNATIONAL CONVENTION FOR THE SAFETY OF LIFE AT SEA, 1974, AS AMENDED 1 GENERAL 1.1 Introduction This part of the International
More informationKaren LeVasseur, LCSW Calm4Kids Therapy Center, LLC 514 Main Street Bradley Beach, NJ
Karen LeVasseur, LCSW Calm4Kids Therapy Center, LLC 514 Main Street Bradley Beach, NJ 07720 732 272 8624 THERAPIST CLIENT SERVICE AGREEMENT/INFORMED CONSENT Welcome to my practice. This document contains
More informationUNIVERSITY COLLEGE OF MEDICAL SCIENCES, DELHI_ PROFORMA FOR INSTITUTIONAL ETHICS COMMITTEE (HR) CLEARANCE OF RESEARCH PROJECTS
Guidelines for submission of Research Project/protocol for PhD/ M.D thesis to Institutional Ethics Committee-Human Research (IEC-HR) for its consideration. 1. All projects/protocols submitted for the consideration
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES WARNING LETTER. (b) (4) clinical investigation (Protocol entitled A Phase II, Multicenter,
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Ronald Bukowski, M.D. 28099 Gates Mills
More informationmanaging or activities.
STANDARD OPERATING PROCEDURE Clinical Research Monitoring TITLE: Site Initiation Visit TITLE: Site Initiation Visit 1. PURPOSE SOP Number: Version: 1.0 MICHR CRM MON 002 Effective Date: 19Dec2013 1.1 This
More informationKBEMS Pilot Programs- Adverse Event Notification
KBEMS Pilot Programs- Adverse Event tification Emergencies and Reporting of Adverse Events The responsible project coordinator must promptly notify the Kentucky Board of EMS & the KCTCS HSRB of any problems
More informationACRIN ADVERSE EVENT REPORTING MANUAL. 1 March 2006 v.3
AMERICAN COLLEGE OF RADIOLOGY IMAGING NETWORK ADVERSE EVENT REPORTING MANUAL 1 Prepared by the American College of Radiology Imaging Network Administrative Center September 2002 Revised March 2006 American
More informationFINAL DOCUMENT. Global Harmonization Task Force
GHTF/SG5/N5:2012 FINAL DOCUMENT Global Harmonization Task Force Title: Reportable Events During Pre-Market Clinical Investigations Authoring Group: Study Group 5 of the Global Harmonization Task Force
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations Dallas Jr, Anthony V, MD 11/09/09 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring,
More informationVersion Number: 003. On: September 2017 Review Date: September 2020 Distribution: Essential Reading for: Information for: Page 1 of 13
CONTROLLED DOCUMENT Reporting Research Incidents and Breaches Policy CATEGORY: CLASSIFICATION: PURPOSE Controlled Number: Document Policy Governance To set out the framework and principles for reporting
More informationThis Agreement dated DD/MM/YYYY (the Effective Date ) is between
Clinical Trial Delegation of Sponsorship Responsibilities to Chief This Agreement dated DD/MM/YYYY (the Effective Date ) is between Nottingham University Hospitals NHS Trust, Derby Road, Nottingham, NG7
More informationTrial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs
R&D Department Trial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored
More informationSTENOGRAPHER REQUEST FOR QUALIFICATIONS (RFQ)
STENOGRAPHER REQUEST FOR QUALIFICATIONS (RFQ) Los Angeles County Children and Families First Proposition 10 Commission (aka First 5 LA) RELEASE DATE: FEBRUARY 11, 2014 TABLE OF CONTENTS I. TIMELINE FOR
More informationRITAZAREM CRF Completion Guidelines
RITAZAREM CRF Completion Guidelines 10 Sept 2013 Version 1.2 Author: Michelle Lewin RITAZAREM Trial Coordinator Michelle.lewin@addenbrookes.nhs.uk Tel: +44(0) 1223 349350 Fax: +44(0) 1223 586767 Version
More informationUtilizing the NCI CIRB
Policy P15 Written By: B. Laurel Elder, Ph.D. Created: September 2, 2011 Edited Version P15.1 Utilizing the NCI CIRB PURPOSE - The purpose of this Standard Operating Procedure (SOP) is to outline the procedures
More informationGUIDANCE DOCUMENT FOR INSTITUTIONAL ETHICS COMMITTEE REVIEWING CLINICAL TRIALS ON HUMAN PARTICIPANTS
GUIDANCE DOCUMENT FOR INSTITUTIONAL ETHICS COMMITTEE REVIEWING CLINICAL TRIALS ON HUMAN PARTICIPANTS December 2015 Page 1 of 56 This document containing operational guidance has been developed for the
More informationThe Queen s Medical Center HIPAA Training Packet for Researchers
The Queen s Medical Center HIPAA Training Packet for Researchers 1 The Queen s Medical Center HIPAA Training Packet for Researchers Table of Contents Overview of HIPAA and Research 3 Penalties for violations
More informationINFORMED CONSENT TO PARTICIPATE IN A DIABETES RESEARCH REGISTRY
INFORMED CONSENT TO PARTICIPATE IN A DIABETES RESEARCH REGISTRY PRINCIPAL INVESTIGATOR: Andrew S. Pumerantz, DO 795 E. Second Street, Suite 4 Pomona, CA 91766-2007 (909) 706-3779 CO-INVESTIGATORS: WDI
More informationAssociates in ear, nose, throat/ Head & Neck surgery, pllc
Associates in ear, nose, throat/ Head & Neck surgery, pllc Notice of Privacy Practices for Protected Health Information Associates in Ear, Nose & Throat (ENT) is providing this Notice to comply with the
More informationSOP Title: Reporting Adverse Events and New Safety Information
Page 1 of 14 General Control of medication use requires collecting field data about adverse events (AEs) resulting from medication therapy. Regulation 7(B)(2) of Pharmacists Regulations (Medical Products)
More informationNABH Accreditation Standards for Clinical Trials and application form. Indian Society for Clinical Research
Indian Society for Clinical Research Recommendations/Suggestions on NABH Accreditation Standards for Clinical Trials (Ethics Committee, Investigator and Clinical Trial Site) and application form Date:
More informationWORKING CONSOLIDATED TEXT
WORKING CONSOLIDATED TEXT Act No. 123/2000 Coll., of 15 April 2000 on medical devices and on amendment to some related acts, as amended by Act No. 130/2003 Coll. and Act No. 274/2003 Coll. *) The Parliament
More informationStandard Operating Procedure IRB Review of Research Subject to the Revised Common Rule
HRP Consulting is providing this sample SOP addendum to assist organizations in the event that the revised Common Rule goes into effect on January 19, 2018. This sample SOP addendum does not address every
More informationPablo Tebas, M.D. Joseph Quinn, RN, BSN Yan Jiang, RN, BSN, MSN
Gilead Sciences, Inc. / Protocol Number GS-US-380-1489 Page 1 of 9 PARTNER PREGNANCY FOLLOW UP CONSENT FORM Sponsor / Study Title: Protocol Number: Principal Investigator: (Study Doctor) Gilead Sciences,
More informationHuman Research Governance Review Policy
Policy Document Title: Document ID: Document Name: Human Research Governance Review Policy PY-RSH-300304 Human Research Governance Review Policy Version Number: 2 Revision Date: Key Words 28/10/2014 10:40:00
More informationSOP MONITORING & OVERSIGHT OF RESEARCH ACTIVITY. Contact Jess Bisset, Research Operations Manager x20227
SOP MONITORING & OVERSIGHT OF RESEARCH ACTIVITY SETTING FOR STAFF QUERIES Trust wide All staff involved in research Contact Jess Bisset, Research Operations Manager x20227 Guidance 1. Introduction In accordance
More informationFrequently Asked Questions. The CIRB is located at 168 Jalan Bukit Merah #06-08 Tower 3 Connection One Singapore
1. Where is the location of the CIRB? The CIRB is located at 168 Jalan Bukit Merah #06-08 Tower 3 Connection One Singapore 150168. 2. When is the submission deadline? The CIRB meets once a month. The submission
More informationEthics Committee Composition Roles & Responsibilities. Dr Girish Dayma Dr Sanjay Juvekar KEM Hospital Research Centre Pune
Ethics Committee Composition Roles & Responsibilities Dr Girish Dayma Dr Sanjay Juvekar KEM Hospital Research Centre Pune Outline Introduction Composition Roles & Responsibilities Overview of amendment
More informationThe Act of 2 July 1999 No. 63 relating to Patients Rights (the Patients Rights Act)
The Act of 2 July 1999 No. 63 relating to Patients Rights (the Patients Rights Act) Chapter 1. General provisions Section 1-1. Object of the Act The object of this Act is to help ensure that all citizens
More informationWIRBinar. How to Survive an FDA Inspection. Upcoming Trainings: Contact Us: (360)
WIRBinar How to Survive an FDA Inspection 10-26-2011 Brought to you by WIRB Education and Consulting Services. Improve your ability to maintain compliance and protect human subjects with guidance from
More informationImplementing the Revised Common Rule Exemptions with Limited IRB Review
Implementing the Revised Common Rule Exemptions with Limited IRB Review Introduction: Four of the exempt categories in the revised Common Rule include a provision for limited IRB review. This resource
More informationResearch Audits PGR. Effective: 12/04/2013 Reviewed: 12/04/2015. Name of Associated Policy: Palmetto Health Administrative Research Review
Effective: 12/04/2013 Reviewed: 12/04/2015 Name of Associated Policy: Palmetto Health Administrative Research Review Definitions Responsible Positions Equipment Needed Procedure Steps, Guidelines, Rules,
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Recording and Reporting Deviations, Violations, Potential Serious Breaches, Serious Breaches and Urgent Safety Measures
More informationTomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan
Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan The views presented in this presentation are those of the author and should not be understood or quoted as being made
More informationPOLICY ON RESEARCH RELATED ADVERSE EVENT REPORTING
POLICY ON RESEARCH RELATED ADVERSE EVENT REPORTING CLASSIFICATION TRUST POLICY NUMBER APPROVING COMMITTEE R & D Governance Committee RATIFYING COMMITTEE Quality & Risk Committee DATE RATIFIED October 2009
More informationGUIDELINES FOR CRITERIA AND CERTIFICATION RULES ANNEX - JAWDA Data Certification for Healthcare Providers - Methodology 2017.
GUIDELINES FOR CRITERIA AND CERTIFICATION RULES ANNEX - JAWDA Data Certification for Healthcare Providers - Methodology 2017 December 2016 Page 1 of 14 1. Contents 1. Contents 2 2. General 3 3. Certification
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL REPORTING OF POST-MARKETING ADVERSE DRUG REACTIONS TO HUMAN MEDICINAL PRODUCTS IN SOUTH AFRICA Important Note: Guideline 2.11 Reporting ADRs in South Africa addresses the reporting
More informationHuman Research Ethics Review Policy
Policy Document Title: Document ID: Document Name: Human Research Ethics Review Policy PY-RSH-300305 Human Research Ethics Review Policy Version Number: 2 Revision Date: Key Words 28/10/2014 10:54:00 AM
More informationArizona Department of Education
State of Arizona Department of Education Request For Grant Application (RFGA) RFGA Number: ED07-0028 RFGA Due Date / Time: Submittal Location: Description of Procurement: February 9, 2007, at 3:00 P.M.
More informationReference Number: UHB 253 Version Number: 1 Date of Next Review: 22/01/2018 Previous Trust/LHB Reference Number: SR-RG-015
Reference Number: UHB 253 Version Number: 1 Date of Next Review: 22/01/2018 Previous Trust/LHB Reference Number: SR-RG-015 Safety Reporting in CTIMPs Standard Operating Procedure Introduction and Aim The
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL POST-MARKETING REPORTING OF ADVERSE DRUG REACTIONS TO HUMAN MEDICINES IN SOUTH AFRICA This document has been prepared to serve as a guideline to those reporting adverse drug reactions.
More informationIRB 101. Rachel Langhofer Joan Rankin Shapiro Research Administration UA College of Medicine - Phoenix
IRB 101 Rachel Langhofer Joan Rankin Shapiro Research Administration UA College of Medicine - Phoenix Contents Brief discussion of regulations IRB Structure Levels of Approval Informed Consent HIPAA/HITECH
More informationNHS RESEARCH PASSPORT POLICY AND PROCEDURE
LEEDS BECKETT UNIVERSITY NHS RESEARCH PASSPORT POLICY AND PROCEDURE www.leedsbeckett.ac.uk/staff 1. Introduction This policy aims to clarify the circumstances in which an NHS Honorary Research Contract
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Recording, Managing and Reporting Adverse Events SOP Number: 2 Version Number: 3.0 Supersedes: 2.1 Effective date: May 2013
More informationUTILIZATION REVIEW DECISIONS ISSUED PRIOR TO JULY 1, 2013 FOR INJURIES OCCURRING PRIOR TO JANUARY 1, 2013
California Utilization Review Plan UTILIZATION REVIEW DECISIONS ISSUED PRIOR TO JULY 1, 2013 FOR INJURIES OCCURRING PRIOR TO JANUARY 1, 2013 GOALS Assure injured workers receive timely and appropriate
More informationColorado Board of Pharmacy Rules pertaining to Collaborative Practice Agreements
6.00.00 PHARMACEUTICAL CARE, DRUG THERAPY MANAGEMENT AND PRACTICE BY PROTOCOL. 6.00.10 Definitions. a. "Pharmaceutical care" means the provision of drug therapy and other pharmaceutical patient care services
More informationNew York Notice Form Notice of Psychologists Policies and Practices to Protect the Privacy of Your Health Information
New York Notice Form Notice of Psychologists Policies and Practices to Protect the Privacy of Your Health Information THIS NOTICE DESCRIBES HOW PSYCHOLOGICAL INFORMATION ABOUT YOU MAY BE USED AND DISCLOSED
More informationNational Police Promotion Framework. Data Capture Force Guidance 2011/2012. May Version 1.3
National Police Promotion Framework Data Capture Force Guidance 2011/2012 May 2011 Version 1.3 National Police Promotion Framework Force Guidance For Data Capture (c) - NPIA (National Policing Improvement
More informationCOATS Coordinating Center Memo #3
TO: COATS Study Coordinators FROM: Kimberly Ring Data Coordinating Center DATE: March 25, 2009 RE: SAE QxQ COATS Coordinating Center Memo #3 This memo addresses the COATS SAE QxQ, which is now available.
More informationStudy Monitoring Plan Template
Study Monitoring Plan Template Sponsor Reference Number: Study Title: Principal Investigator: Study Centre: The Sponsor risk assessment form and the trial risk based monitoring strategy appendices 2 &
More informationPatient s Guide to The Waiting Room. Version 1.1 Date: 17-Feb-17
Patient s Guide to The Waiting Room Version 1.1 Date: 17-Feb-17 Contents Registering for The Waiting Room with your practice... 3 Account Details... 4 Creating an account at TWR... 4 First visit to The
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility
General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and
More information